SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer

There was a case report showed that a novel pleckstrin homology and RUN domain containing M2 (PLEKHM2)- anaplastic lymphoma kinase (ALK) gene rearrangement in small cell lung cancer (SCLC) patient had long-term benefit from ALK inhibitors [1]. Actually, the case report demonstrated that next generation sequence (NGS) maybe a very useful method for detecting a new subtype of ALK fusion and it may provide a better understanding of ALK- tyrosine kinase inhibitors (TKIs) treatment. Here, we identified a novel type of ALK rearrangement responding to ALK inhibitors in non-small cell lung cancer (NSCLC) by NGS.

Source: Lung Cancer - March 16, 2020 Category: Cancer & Oncology Authors: Li Ma, Quan Zhang, Yujie Dong, Haoyang Li, Jinghui Wang Source Type: research